Literature DB >> 32373932

Reduction in Baseline CD4 Count Testing Following Human Immunodeficiency Virus "Treat All" Adoption in Uganda.

Esther Nasuuna1, Mark W Tenforde2,3, Alex Muganzi1, Joseph N Jarvis4,5, Yukari C Manabe1,6, Joanita Kigozi1.   

Abstract

Baseline CD4 testing rates declined from 73% to 21% between 2013 and 2018 with adoption of "Treat All" in Uganda. Advanced human immunodeficiency virus (HIV) disease (CD4 count < 200 cells/µL) remained common (24% of those tested in 2018, 83% of whom had World Health Organization stage I/II disease). Despite frequent presentation with advanced HIV disease, CD4 testing has declined dramatically.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  CD4; HIV; opportunistic infections; test-and-treat; treat all

Mesh：

Year:  2020        PMID： 32373932      PMCID： PMC7713677          DOI： 10.1093/cid/ciaa261

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  9 in total

1.  Cryptococcal meningitis screening and community-based early adherence support in people with advanced HIV infection starting antiretroviral therapy in Tanzania and Zambia: an open-label, randomised controlled trial.

Authors:  Sayoki Mfinanga; Duncan Chanda; Sokoine L Kivuyo; Lorna Guinness; Christian Bottomley; Victoria Simms; Carol Chijoka; Ayubu Masasi; Godfather Kimaro; Bernard Ngowi; Amos Kahwa; Peter Mwaba; Thomas S Harrison; Saidi Egwaga; Shabbar Jaffar
Journal:  Lancet       Date:  2015-03-10       Impact factor: 79.321

2.  Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort.

Authors:  A S Walker; D Ford; C F Gilks; P Munderi; F Ssali; A Reid; E Katabira; H Grosskurth; P Mugyenyi; J Hakim; J H Darbyshire; D M Gibb; A G Babiker
Journal:  Lancet       Date:  2010-03-27       Impact factor: 79.321

3.  Effect on mortality of point-of-care, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV-positive hospital inpatients: a pragmatic, parallel-group, multicountry, open-label, randomised controlled trial.

Authors:  Jonny G Peter; Lynn S Zijenah; Duncan Chanda; Petra Clowes; Maia Lesosky; Phindile Gina; Nirja Mehta; Greg Calligaro; Carl J Lombard; Gerard Kadzirange; Tsitsi Bandason; Abidan Chansa; Namakando Liusha; Chacha Mangu; Bariki Mtafya; Henry Msila; Andrea Rachow; Michael Hoelscher; Peter Mwaba; Grant Theron; Keertan Dheda
Journal:  Lancet       Date:  2016-03-10       Impact factor: 79.321

Review 4.  Diagnostic accuracy of the WHO clinical staging system for defining eligibility for ART in sub-Saharan Africa: a systematic review and meta-analysis.

Authors:  Chigomezgo Munthali; Miriam Taegtmeyer; Paul G Garner; David G Lalloo; S Bertel Squire; Elizabeth L Corbett; Nathan Ford; Peter MacPherson
Journal:  J Int AIDS Soc       Date:  2014-06-12       Impact factor: 5.396

5.  Persistent High Burden of Advanced HIV Disease Among Patients Seeking Care in South Africa's National HIV Program: Data From a Nationwide Laboratory Cohort.

Authors:  Sergio Carmona; Jacob Bor; Cornelius Nattey; Brendan Maughan-Brown; Mhairi Maskew; Matthew P Fox; Deborah K Glencross; Nathan Ford; William B MacLeod
Journal:  Clin Infect Dis       Date:  2018-03-04       Impact factor: 20.999

6.  Advanced Human Immunodeficiency Virus Disease at Diagnosis in Mozambique and Swaziland.

Authors:  Stephanie A Kujawski; Matthew R Lamb; Maria Lahuerta; Margaret L McNairy; Laurence Ahoua; Fatima Abacassamo; Harriet Nuwagaba-Biribonwoha; Averie Gachuhi; Wafaa M El-Sadr; Batya Elul
Journal:  Open Forum Infect Dis       Date:  2017-07-23       Impact factor: 3.835

7.  Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa.

Authors:  James Hakim; Victor Musiime; Alex J Szubert; Jane Mallewa; Abraham Siika; Clara Agutu; Simon Walker; Sarah L Pett; Mutsa Bwakura-Dangarembizi; Abbas Lugemwa; Symon Kaunda; Mercy Karoney; Godfrey Musoro; Sheila Kabahenda; Kusum Nathoo; Kathryn Maitland; Anna Griffiths; Margaret J Thomason; Cissy Kityo; Peter Mugyenyi; Andrew J Prendergast; A Sarah Walker; Diana M Gibb
Journal:  N Engl J Med       Date:  2017-07-20       Impact factor: 91.245

8.  Reduction in early mortality on antiretroviral therapy for adults in rural South Africa since change in CD4+ cell count eligibility criteria.

Authors:  Richard J Lessells; Portia C Mutevedzi; Collins C Iwuji; Marie-Louise Newell
Journal:  J Acquir Immune Defic Syndr       Date:  2014-01-01       Impact factor: 3.731

9.  Rapid urine-based screening for tuberculosis in HIV-positive patients admitted to hospital in Africa (STAMP): a pragmatic, multicentre, parallel-group, double-blind, randomised controlled trial.

Authors:  Ankur Gupta-Wright; Elizabeth L Corbett; Joep J van Oosterhout; Douglas Wilson; Daniel Grint; Melanie Alufandika-Moyo; Jurgens A Peters; Lingstone Chiume; Clare Flach; Stephen D Lawn; Katherine Fielding
Journal:  Lancet       Date:  2018-07-20       Impact factor: 79.321
  9 in total
  3 in total

1.  Effects of implementing universal and rapid HIV treatment on initiation of antiretroviral therapy and retention in care in Zambia: a natural experiment using regression discontinuity.

Authors:  Aaloke Mody; Izukanji Sikazwe; Angella Sandra Namwase; Mwanza Wa Mwanza; Theodora Savory; Annie Mwila; Lloyd Mulenga; Michael E Herce; Keith Mweebo; Paul Somwe; Ingrid Eshun-Wilson; Kombatende Sikombe; Laura K Beres; Jake Pry; Charles B Holmes; Carolyn Bolton-Moore; Elvin H Geng
Journal:  Lancet HIV       Date:  2021-10-14       Impact factor: 12.767

2.  The Enduring Burden of Advanced Human Immunodeficiency Virus Disease.

Authors:  Nathan Ford; Eric Goemaere; Katherine Hildebrand; Carmen Perez-Casas
Journal:  Clin Infect Dis       Date:  2020-12-03       Impact factor: 9.079

3.  Utility of CD4 count measurement in the era of universal antiretroviral therapy: an analysis of routine laboratory data in Botswana.

Authors:  T B Leeme; M Mine; K Lechiile; F Mulenga; M Mosepele; T Mphoyakgosi; C Muthoga; J Ngidi; B Nkomo; D Ramaabya; M Tau; M W Tenforde; R Hayes; J N Jarvis
Journal:  HIV Med       Date:  2020-09-02       Impact factor: 3.094
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.